These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24674587)

  • 21. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice.
    Merani S; Truong W; Emamaullee JA; Toso C; Knudsen LB; Shapiro AM
    Endocrinology; 2008 Sep; 149(9):4322-8. PubMed ID: 18511515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of a novel congenic strain of diabetic fatty (WBN/Kob-Lepr(fa)) rat.
    Akimoto T; Nakama K; Katsuta Y; Zhang XJ; Ohsuga M; Ishizaki M; Sawai N; Ozawa H
    Biochem Biophys Res Commun; 2008 Feb; 366(2):556-62. PubMed ID: 18068663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
    Porter DW; Kerr BD; Flatt PR; Holscher C; Gault VA
    Diabetes Obes Metab; 2010 Oct; 12(10):891-9. PubMed ID: 20920042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.
    Raun K; von Voss P; Knudsen LB
    Obesity (Silver Spring); 2007 Jul; 15(7):1710-6. PubMed ID: 17636089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
    Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
    Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of insulin resistance in the pathogenesis and development of type 2 diabetes in WBN/Kob-Lepr(fa) rats.
    Okuno A; Kaji N; Takahashi A; Nagakubo D; Ohno-Ichiki K; Shirai M; Asai F
    J Vet Med Sci; 2013 Dec; 75(12):1557-61. PubMed ID: 23892462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice.
    Chen LN; Lyu J; Yang XF; Ji WJ; Yuan BX; Chen MX; Ma X; Wang B
    Int J Mol Med; 2013 Oct; 32(4):892-900. PubMed ID: 23877319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats.
    Swarbrick MM; Cox CL; Graham JL; Knudsen LB; Stanhope K; Raun K; Havel PJ
    Endocrinol Diabetes Metab; 2023 Jan; 6(1):e392. PubMed ID: 36480511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
    Ellenbroek JH; Töns HA; Westerouen van Meeteren MJ; de Graaf N; Hanegraaf MA; Rabelink TJ; Carlotti F; de Koning EJ
    Diabetologia; 2013 Sep; 56(9):1980-6. PubMed ID: 23771206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia.
    Meek TH; Dorfman MD; Matsen ME; Fischer JD; Cubelo A; Kumar MR; Taborsky GJ; Morton GJ
    Diabetes; 2015 Jul; 64(7):2376-87. PubMed ID: 25633417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of high-fat diet and fructose-rich diet on obesity, dyslipidemia and hyperglycemia in the WBN/Kob-Lepr
    Namekawa J; Takagi Y; Wakabayashi K; Nakamura Y; Watanabe A; Nagakubo D; Shirai M; Asai F
    J Vet Med Sci; 2017 Jun; 79(6):988-991. PubMed ID: 28442647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.
    Sturis J; Gotfredsen CF; Rømer J; Rolin B; Ribel U; Brand CL; Wilken M; Wassermann K; Deacon CF; Carr RD; Knudsen LB
    Br J Pharmacol; 2003 Sep; 140(1):123-32. PubMed ID: 12967942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
    Kim SH; Liu A; Ariel D; Abbasi F; Lamendola C; Grove K; Tomasso V; Reaven G
    Diabetologia; 2014 Mar; 57(3):455-62. PubMed ID: 24326527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
    Mells JE; Fu PP; Sharma S; Olson D; Cheng L; Handy JA; Saxena NK; Sorescu D; Anania FA
    Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(2):G225-35. PubMed ID: 22038829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
    González C; Beruto V; Keller G; Santoro S; Di Girolamo G
    Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.